In recent years, liquid biopsies have emerged as a promising tool in the fields of molecular oncology and precision medicine. Liquid biopsy methodology typically analyses genomic DNA isolated from circulating tumour cells (CTCs) or circulating cell-free tumour DNA (cfDNA/ctDNA) in a peripheral blood sample, to gain insight into the genomic profile of the patients’ tumour.

Liquid biopsy for non-small cell lung cancer